Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Gogas

Showing results (71-80 of 93) with videos related to

Pageof 10
Sort By:
European Journal of Cancer (Oxford, England : 1990)|December 4, 2012
Obesity and risk of malignant melanoma: a meta-analysis of cohort and case-control studiesTheodoros N Sergentanis, Antonios G Antoniadis, Helen J Gogas, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 15, 1993
Expression of alpha-thymosins in human tissues in normal and abnormal growthO E Tsitsiloni, J Stiakakis, A Koutselinis, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 10, 2008
Next generation of immunotherapy for melanomaJohn M Kirkwood, Ahmad A Tarhini, Monica C Panelli, et al.
Anticancer Research|July 23, 1998
The prognostic value of alpha-thymosins in breast cancerO E Tsitsilonis, E Bekris, I F Voutsas, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 13, 2002
Liposomal doxorubicin in conjunction with reirradiation and local hyperthermia treatment in recurrent breast cancer: a phase I/II trialVassilios E Kouloulias, Costas E Dardoufas, John R Kouvaris, et al.
European Journal of Cancer (Oxford, England : 1990)|January 6, 2020
Update on tolerability and overall survival in COLUMBUS: landmark analysis of a randomised phase 3 trial of encorafenib plus binimetinib vs vemurafenib or encorafenib in patients with BRAF V600-mutant melanomaPaolo A Ascierto, Reinhard Dummer, Helen J Gogas, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 28, 2023
Contribution of MEK Inhibition to BRAF/MEK Inhibitor Combination Treatment of <i>BRAF</i>-Mutant Melanoma: Part 2 of the Randomized, Open-Label, Phase III COLUMBUS TrialPaolo A Ascierto, Reinhard Dummer, Helen J Gogas, et al.
Future Oncology (London, England)|June 13, 2023
COLUMBUS 5-year update: a randomized, open-label, phase III trial of encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAFReinhard Dummer, Keith T Flaherty, Caroline Robert, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 21, 2022
COLUMBUS 5-Year Update: A Randomized, Open-Label, Phase III Trial of Encorafenib Plus Binimetinib Versus Vemurafenib or Encorafenib in Patients With <i>BRAF</i> V600-Mutant MelanomaReinhard Dummer, Keith T Flaherty, Caroline Robert, et al.
Future Oncology (London, England)|January 15, 2025
A plain language summary of the 7-year update from part 1 of the COLUMBUS study: encorafenib and binimetinib for people with BRAF V600-mutant melanomaDirk Schadendorf, Reinhard Dummer, Keith T Flaherty, et al.
Pageof 10

Showing results (71-80 of 93) with videos related to

Sort By:
Pageof 10
European Journal of Cancer (Oxford, England : 1990)|December 4, 2012
Obesity and risk of malignant melanoma: a meta-analysis of cohort and case-control studiesTheodoros N Sergentanis, Antonios G Antoniadis, Helen J Gogas, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 15, 1993
Expression of alpha-thymosins in human tissues in normal and abnormal growthO E Tsitsiloni, J Stiakakis, A Koutselinis, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 10, 2008
Next generation of immunotherapy for melanomaJohn M Kirkwood, Ahmad A Tarhini, Monica C Panelli, et al.
Anticancer Research|July 23, 1998
The prognostic value of alpha-thymosins in breast cancerO E Tsitsilonis, E Bekris, I F Voutsas, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 13, 2002
Liposomal doxorubicin in conjunction with reirradiation and local hyperthermia treatment in recurrent breast cancer: a phase I/II trialVassilios E Kouloulias, Costas E Dardoufas, John R Kouvaris, et al.
European Journal of Cancer (Oxford, England : 1990)|January 6, 2020
Update on tolerability and overall survival in COLUMBUS: landmark analysis of a randomised phase 3 trial of encorafenib plus binimetinib vs vemurafenib or encorafenib in patients with BRAF V600-mutant melanomaPaolo A Ascierto, Reinhard Dummer, Helen J Gogas, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 28, 2023
Contribution of MEK Inhibition to BRAF/MEK Inhibitor Combination Treatment of <i>BRAF</i>-Mutant Melanoma: Part 2 of the Randomized, Open-Label, Phase III COLUMBUS TrialPaolo A Ascierto, Reinhard Dummer, Helen J Gogas, et al.
Future Oncology (London, England)|June 13, 2023
COLUMBUS 5-year update: a randomized, open-label, phase III trial of encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAFReinhard Dummer, Keith T Flaherty, Caroline Robert, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 21, 2022
COLUMBUS 5-Year Update: A Randomized, Open-Label, Phase III Trial of Encorafenib Plus Binimetinib Versus Vemurafenib or Encorafenib in Patients With <i>BRAF</i> V600-Mutant MelanomaReinhard Dummer, Keith T Flaherty, Caroline Robert, et al.
Future Oncology (London, England)|January 15, 2025
A plain language summary of the 7-year update from part 1 of the COLUMBUS study: encorafenib and binimetinib for people with BRAF V600-mutant melanomaDirk Schadendorf, Reinhard Dummer, Keith T Flaherty, et al.
Pageof 10